The NRIF3/DD1/DIF-1/FASTKD2 pathway is a new pathway to therapeutically target Estrogen Receptor negative breast or androgen independent prostate cancer or metastatic cancer for therapy. This evidence concerns the gene FASTKD2 and metastatic malignant neoplasm.